AAN 2025 | Advancing precision migraine treatment with AI
Chia-Chun Chiang, MD, Mayo Clinic, Rochester, MN, comments on the challenges of migraine treatment, highlighting the need for more accurate prediction of which patients will respond best to different medications. Dr Chiang emphasizes the importance of advancing precision migraine treatment, which could help shorten the trial-and-error process and improve patient outcomes. Another significant challenge is the need to develop new, migraine-specific treatment targets, as many patients do not respond to current medications. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Currently in clinical practice we have so many medications that are available and that can be used as a migraine preventive treatment. However, there is no way to accurately predict which patients would best respond to what medications. So currently in our practice, we choose among those medications based on the patient’s clinical characteristics, their comorbidities, and the patient’s preference...
Currently in clinical practice we have so many medications that are available and that can be used as a migraine preventive treatment. However, there is no way to accurately predict which patients would best respond to what medications. So currently in our practice, we choose among those medications based on the patient’s clinical characteristics, their comorbidities, and the patient’s preference. However, I think the importance of the studies like that, advancing precision migraine treatment, could really help us shorten this trial and error process and help patients get to the right medication for each individual at the very beginning because currently, the biggest challenge in our practice is that a lot of times we say, OK, you might start with this medication. And if this medication doesn’t work, you come back in three months, then we would prescribe another medication. And if this medication doesn’t work, then we would prescribe a third medication. So this trial and error process might continue for a long period of time. So I think that is one challenge that we currently identify in clinical practice. So research like that, the study that I just discussed, using AI to advance precision migraine treatment, becomes very important, and I do have a current ongoing effort to push those studies forward to help to further advance individualized treatment for patients with migraine. So I think that is one big challenge. Another big challenge is that despite having many migraine preventive treatments that are available, because we are a tertiary headache center in our practice, we see a lot of patients that have used most of these treatment options available, but still don’t get adequate control of their migraine. So I think another barrier is to really advance the field and identify and develop new treatment targets for migraine that are migraine-specific medications, and hopefully that can help with more patients that do not currently respond to the medications that are currently available and then further advance how we can keep the patient’s migraine under control and help to advance the quality of life for these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultant: Satsuma, eNeura, Pfizer.
